Krystexxa pegloticase regulatory update

Savient's Savient Pharma Ireland Ltd. subsidiary began a named-patient program in the EU to provide access to Krystexxa pegloticase to treat refractory chronic gout. Idis Ltd. (Weybridge, U.K.) will m...